Sign In  |  Register  |  About Menlo Park  |  Contact Us

Menlo Park, CA
September 01, 2020 1:28pm
7-Day Forecast | Traffic

  • Search Hotels in Menlo Park

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Catalyst Pharm Inc (NQ: CPRX )

15.80 +0.49 (+3.20%)
Streaming Delayed Price Updated: 4:00 PM EST, Feb 2, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 2,786,913
Open 15.25
Bid (Size) 15.40 (1)
Ask (Size) 15.85 (3)
Prev. Close 15.31
Today's Range 15.11 - 15.92
52wk Range 5.580 - 22.11
Shares Outstanding 102,780,151
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Stock Market Rally Powers Higher Amid Big Earnings From Tesla, Boeing, Microsoft, American Express: Weekly Review
Stocks reacted well to uneven earnings and economic reports. 
Via Investor's Business Daily
Down 30% in a Day, Is Catalyst Pharmaceuticals Doomed?
Things aren't as bad as they might seem. 
Via The Motley Fool

Performance

YTD
-12.51%
-12.51%
1 Month
-12.51%
-12.51%
3 Month
+13.02%
+13.02%
6 Month
+46.70%
+46.70%
1 Year
+172.88%
+172.88%

More News

Read More
Here's How Much $1000 Invested In Catalyst Pharmaceuticals 15 Years Ago Would Be Worth Today
Via Benzinga
How Former IBD 50 Leader Catalyst Pharma Is Trying To Claw Back From A 29% Setback
Via Investor's Business Daily
$1000 Invested In This Stock 10 Years Ago Would Be Worth $27,000 Today
Via Benzinga
Analyst Expectations for Catalyst Pharmaceuticals's Future
Via Benzinga
HC Wainwright & Co. Maintains Buy Rating for Catalyst Pharmaceuticals: Here's What You Need To Know
Via Benzinga
Catalyst Pharmaceuticals Completes the Acquisition of U.S. Rights to FYCOMPA® (Perampanel) CIII
From Catalyst Pharmaceuticals, Inc.
Via Globe NewsWire
Pliant Therapeutics Gaps 34% Higher: More Upside To Come?
Via MarketBeat
Nasdaq Rises 1.5%; Pliant Therapeutics Shares Spike Higher
Via Benzinga
Catalyst Pharmaceuticals Comments on FDA's Announcement of its Position on Orphan Drug Exclusivity In Light of the 11th Circuit Decision in Catalyst Pharmaceuticals, Inc. v. Becerra
From Catalyst Pharmaceuticals, Inc.
Via Globe NewsWire
Why Evoqua Water Technologies Shares Are Trading Higher By 10%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Via Benzinga
Dow, Nasdaq Boasting Triple-Digit Midday Lead
Via Talk Markets
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
Dow Jumps Over 300 Points; Crude Oil Up 1%
Via Benzinga
Catalyst Pharmaceuticals, Xylem And Other Big Stocks Moving Lower On Monday
Via Benzinga
Catalyst Pharma Shares Take A Hit As Teva Files For Generic Version Of Its Lead Product
Via Benzinga
US Stocks Mostly Higher; Synchrony Financial Earnings Top Views
Via Benzinga
No. 1 IBD 50 Stock Catalyst Tanks As Teva Looks To Knock Off Its Only Product
Via Investor's Business Daily
Why Catalyst Pharmaceuticals Shares Are Moving
Via Benzinga
Catalyst Pharmaceuticals Notified of Abbreviated New Drug Application Filing for FIRDAPSE®
From Catalyst Pharmaceuticals, Inc.
Via Globe NewsWire
2 Biotechs Making Waves With A Single Product in their Pipeline
Via MarketBeat
IDEXX Laboratories Stock Clears Technical Benchmark, Hitting 80-Plus RS Rating
Via Investor's Business Daily
Top Picks For 2023: Catalyst Pharmaceuticals - Sunday, Jan. 8
Via Talk Markets
Top Picks For 2023: Catalyst Pharmaceuticals
Via Talk Markets
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 MenloPark.com & California Media Partners, LLC. All rights reserved.